Related Experiment Video
Updated: Nov 9, 2025

High-resolution Respirometry to Measure Mitochondrial Function of Intact Beta Cells in the Presence of Natural Compounds
Published on: January 23, 2018
Glucotoxicity-induced suppression of Cox6a2 expression provokes β-cell dysfunction via augmented ROS production
Yasuki Nagai1, Taka-Aki Matsuoka2, Naoki Shimo1
1Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan.
Abstract:
Oxidative stress is a deteriorating factor for pancreatic β-cells under chronic hyperglycemia in diabetes. However, the molecular mechanism underlying the increase in oxidative stress in β-cells under diabetic conditions remains unclear. We demonstrated previously that the selective alleviation of glucotoxicity ameliorated the downregulation of several β-cell factors, including Cox6a2. Cox6a2 encodes a subunit of the respiratory chain complex IV in mitochondria. In this study, we analyzed the role of Cox6a2 in pancreatic β-cell function and its pathophysiological significance in diabetes mellitus. Cox6a2-knockdown experiments in MIN6-CB4 cells indicated an increased production of reactive oxygen species as detected by CellROX Deep Red reagent using flow cytometry. In systemic Cox6a2-knockout mice, impaired glucose tolerance was observed under a high-fat high-sucrose diet. However, insulin resistance was reduced when compared with control littermates. This indicates a relative insufficiency of β-cell function. To examine the transcriptional regulation of Cox6a2, ATAC-seq with islet DNA was performed and an open-chromatin area within the Cox6a2 enhancer region was detected. Reporter gene analysis using this area revealed that MafA directly regulates Cox6a2 expression. These findings suggest that the decreased expression of Cox6a2 increases the levels of reactive oxygen species and that Mafa is associated with decreased Cox6a2 expression under glucotoxic conditions.
Insights
Decreased Cox6a2 expression in pancreatic cells elevates oxidative stress, impairing glucose tolerance in diabetes. MafA transcription factor directly regulates Cox6a2, suggesting a mechanism for beta-cell dysfunction.
Area of Science:
- Cellular biology
- Mitochondrial function
- Diabetes mellitus research
Background:
- Oxidative stress damages pancreatic beta-cells in diabetes.
- The precise molecular mechanisms driving this oxidative stress are not fully understood.
- Previous work indicated Cox6a2 downregulation under glucotoxicity.
Purpose of the Study:
- To investigate the role of Cox6a2 in pancreatic beta-cell function.
- To elucidate the pathophysiological significance of Cox6a2 in diabetes mellitus.
- To identify the transcriptional regulation of Cox6a2.
Main Methods:
- Cox6a2 knockdown in MIN6-CB4 cells.
- Reactive oxygen species detection using CellROX Deep Red reagent and flow cytometry.
- Analysis of Cox6a2-knockout mice fed a high-fat, high-sucrose diet.
- ATAC-seq on islet DNA and reporter gene assays.
Main Results:
- Cox6a2 knockdown increased reactive oxygen species production.
- Cox6a2-knockout mice exhibited impaired glucose tolerance.
- MafA was identified as a direct regulator of Cox6a2 expression.
- MafA is linked to reduced Cox6a2 expression under glucotoxic conditions.
Conclusions:
- Reduced Cox6a2 expression contributes to increased reactive oxygen species in beta-cells.
- MafA directly regulates Cox6a2, implicating it in beta-cell dysfunction during diabetes.
- Findings highlight Cox6a2 as a potential target for managing diabetic complications.
Related Concept Videos
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Cell Specific Gene Expression
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hypoglycemia and Glucagon

